Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Intelligent Capsule to Enable Noninvasive Sampling of Intestinal Microorganisms

By BiotechDaily International staff writers
Posted on 15 Apr 2013
Print article
Image: The IntelliCap capsule (Photo courtesy of Medimetrics Personalized Drug Delivery BV).
Image: The IntelliCap capsule (Photo courtesy of Medimetrics Personalized Drug Delivery BV).
Two Dutch companies are collaborating on a project that will establish a noninvasive method for studying how foods and food additives affect the microbes that regulate the digestive process in the small intestine.

NIZO Food Research (Ede, [Food Valley], The Netherlands) and Medimetrics (Eindhoven, The Netherlands) are generating new applications for the Medimetrics' IntelliCap system, which is currently used by the pharmaceutical industry for the targeted and controlled delivery of drugs in the human gastrointestinal tract.

The IntelliCap capsule is a tiny, pill-shaped (11 x 26 mm) microelectronic instrument that is swallowed by the test subject. The capsule then passes through the digestive tract by peristalsis. Samples, which are documented by transit time, pH level, and temperature, are collected and held in separate compartments

After being excreted by the test subject, a quantitative and representative map of each sample’s microbiological molecular composition will be generated using methodology developed by NIZO.

“By assessing the way food and probiotics affect microbiota composition inside the small intestine of healthy individuals, we can better decipher the mechanisms which influence gut health, host metabolism, and immunity,” said Dr. Harro Timmerman, a principle researcher at NIZO. “We may even access new markers which enable us to substantiate claims regarding the health properties of certain foods.”

Dr. Christoph Wanke, clinical program leader at Medimetrics, said, “Food scientists wanting to develop functional foods immediately see the potential of the IntelliCap technology in enabling them to apply it as a novel tool to characterize the gut microbiome. In addition, considering its established functionality as a targeted, oral delivery device, we can see further extensions of the technology in relation to health and disease. This offers the potential to explore novel therapeutic approaches which would enable clinicians to control the microbiological composition of the gut in the treatment of diseases like obesity and diabetes.”

Related Links:
NIZO Food Research
Medimetrics


Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Drug Discovery

view channel
Image: Naturally occurring clay from Kisameet Bay, Canada, exhibits potent antibacterial activity against multidrug-resistant pathogens (Photo courtesy of Kisameet Glacial Clay Inc.).

Antibiotic Resistant Bacteria Succumb to Treatment with Unique Natural Clay

A team of Canadian medical microbiologists has demonstrated the potential use of a unique type of natural clay for treating pathogenic bacteria that have become resistant to the commonly used antibiotics.... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.